The global Spinal Muscular Atrophy (SMA) treatment market is projected to grow at a considerable CAGR of more than 10% during the forecast period (2019-2025). The high incidence of the spinal muscular atrophy and the growing awareness among people related to its diagnosis and treatment are the key factors to drive the growth of the global SMA treatment market. According to the National Organization of Spinal Muscular Atrophy, the incidence of SMA is 1 in 6,000 to 1 in 10,000 live births with a carrier frequency of 1/40-1/60. SMA is a group of inherited diseases that affects the functioning of muscles due to deterioration that result in weakness and may cause death of the patients. The increasing in research R&D activities related to the development of therapies and treatment options by the major market players is anticipated to fuel the market during the forecast period. 

The considerable number of several drugs in pipeline for advanced stages of clinical trials by some of the key pharmaceutical companies will accelerate the demand of the spinal muscular atrophy treatment market. For instance, in November 2019, F. Hoffman La Roche’s pipeline candidate of Risdiplam, which recently received a review from the FDA and is anticipated to receive FDA approval by end of May 2020. Furthermore, the growing number of initiatives related to the pre-diagnosis and positive reimbursement policies is again fuelling the market growth. The high cost of treatment of SMA is a major factor that may restrain its market growth. However, the growing awareness related to treatment of this disease to create new opportunities for the market growth during the forecast period.

Segmental Outlook  

The SMA market is segmented on the basis of treatment type, and disease type. Based on treatment the market is segmented into gene therapy and drugs. Gene therapy is anticipated to be considerable segment during the forecast period. Gene therapy is more costlier than drug however it is also more effective than drug treatment. Based on disease type the market is segmented into type l, type ll, type lll, and type lV.

Type l will be considerable segment by Disease type

Based on disease type, the type l is anticipated to hold major market share during the forecast period. Type l is the most common type of SMA disease and occurs to the children below 6 months. The increasing prevalence of type l SMA disease, on-going R&D activities, and a high number of drugs in clinical pipeline are some of the key factors to drive the growth of this market segment. 

Global SMA Market Share by Disease Type, 2018 (%)

Regional Outlook 

The global SMA market is further segmented on the basis of geography including North America, Europe, Asia-Pacific and Rest of the World. North America is anticipated to hold a major market share in the global SMA market during the forecast period. The presence of key market players of the SMA market including Abbott Laboratories, Biogen, Inc., Novartis AG, and Genetec Inc. in the region have been a catalyzing agent to the growth of the market. The proper medical reimbursement policy, high disposable income, and rise in the adoption of Spinraza in the region further promote the growth of the regional market. The increasing number of initiatives taken by private organizations to create awareness related to this disorder further supports the growth of the market in North America. For example, Cure SMA is a private organization that are offering funding and supporting comprehensive research to accelarate the treatment for SMA patients and their families. North America is followed by Europe and the Asia Pacific is projected to be the fastest-growing market during the forecasted period.

Global SMA Market Growth, by Region 2019-2025

Asia-Pacific will augment with the significant growth rate in the SMA market 

Asia-Pacific is projected to witness a significant growth rate over the forecast period. The rising awareness among the population related to the diagnostics and treatment of SMA in the emerging countries of the region including China, India, and South Korea is anticipated to make major contribution towards the growth of the SMA in Asia-Pacific. The presence of a large targeted patientpool along with cohesive government initiatives in the form of funding and strict laws is anticipated to fuel the market growth in the SMA market.

Market Players Outlook

The Key players of SMA market include Biogen, Inc., Ionis Pharmaceuticals, Inc., Pfizer, Inc., F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Genetec, Inc., Cytokinetics, Inc., Abbott Laboratories, PRA Health Sciences Inc., Cure SMA, Boston Scientific Corp.and so on. These key market players are actively adopting strategic growth activities including mergers and acquisitions, partnerships and collaboration among others to increase their market share. The FDA approvalfor new product launches is the core strength of these key market players to remain competitive in the market. For instance, In May 2019, Novartis AG had received the FDA approval forits first gene therapy, Zolgensma (onasemnogeneabeparvovec-xioi). This therapy is used to treat children less than two years of age with spinal muscular atrophy (SMA). The SMA that occurs under this age is the most critical form of SMA and is the major genetic cause of infant mortality.

The Report Covers

• Annualized market revenues ($ billion) for each market segment. 
• Market value data analysis from 2018 to 2019 and forecast to 2025.
• Company share and market share data for the global SMA market.
• Global corporate-level profiles of key companies operating within the global SMA market. 
• Based on the availability of data for the category and country, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.
• Investment strategies by identifying the key market segments expected to register strong growth in the near future.
• Understand the key distribution channels and identifying the most preferred mode of product distribution.